GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder

Journal of Clinical Investigation

Volumn 108, Issue 6, 2001, Pages 887-894

  Baiocchi, R A ^a   Ward, J S ^a   Carrodeguas, L ^a   Eisenbeis, C F ^a   Peng, R ^a   Roychowdhury, S ^a   Vourganti, S ^a   Sekula, T ^a   O'Brien, M ^a   Moeschberger, M ^a   Caligiuri, M A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; EPSTEIN BARR VIRUS; IMMUNE DEFICIENCY; IMMUNOTHERAPY; LYMPHOCYTE SUBPOPULATION; LYMPHOPROLIFERATIVE DISEASE; MONOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE;

ANIMALS; DISEASE MODELS, ANIMAL; EPSTEIN-BARR VIRUS INFECTIONS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTE TRANSFUSION; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, SCID; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0034821960     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200112932     Document Type: Article

References (52)

1. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients
2. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation
3. Post-transplant lymphoproliferative disorders following renal allografting: Prospective immunological and molecular monitoring identifies correlates of clinical response to reduction of immune suppression and antiviral therapy
4. Endogenous CD8+ T cell expansion during Epstein-Bart virus-associated posttransplant lymphoproliferative disorder
5. Diagnosis and treatment of transplant related lymphoma
6. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: Implications for the pathogenesis of EBV-positive lymphomas in man
7. Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10
8. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes
9. Phenotypic and functional analysis of fas(CD95) expression in primary central nervous system lymphoma of patients with Acquired Immune Deficiency Syndrome
10. Evidence of functional lymphocytes in some (leaky) scid mice
11. Transfer of a functional human immune system to mice with severe combined immunodeficiency
12. In vivo effect of anti-asialo GM1 antibody on natural killer cell activity
13. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice
14. Cell preparation for the identification of leukocytes
15. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity
16. Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice. I. T lymphocyte requirement for B cell tumor generation
17. A phenotypic study of cells from Burkitt lymphoma and EBV-B-lymphoblastoid lines and their relationship to cells in normal lymphoid tissues
18. Cell phenotype (CD23)-dependent variation in EBV genome copy numbers within lymphoblastoid cell lines (LCL)
19. The human immune system in hu-PBL-SCID mice
20. Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicity
21. Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor-alpha and interferon in cancer patients
22. Granulocyte-macrophage colony-stimulating factor enhances selective effector functions of tissue-derived macrophages
23. Effects of continuous high dose rhGM-CSF on human monocyte activity
24. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon gamma by natural killer cells in vitro
25. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor
26. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: Implications for the innate immune response
27. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function
28. Administration of rHuGM-CSF activates monocyte reactive oxygen species secretion and adhesion molecule expression in vivo in patients following high-dose chemotherapy
29. Coinduction of granulocyte-macrophage colony-stimulating factor release and lymphokine-activated killer cell susceptibility, in monocytes by interleukin-2 via interleukin-2 receptor beta
30. IFN-alpha and IFN-gamma can affect both monocytes and tumor cells to modulate monocytes mediated cytotoxicity
31. Human monocyte binding to fibronectin enhances. IFN-gamma-induced early signaling events
32. IFN gamma-induced production of monocyte cytotoxic factor
33. Cytokine regulation of human, monocyte differentiation in vitro: The tumor-cytotoxic phenotype induced by macrophage colony-stimulating factor is developmentally regulated by gamma interferon
34. Multiple roles of interferon-g in the mediation of interleukin 12-induced tumor regression
35. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: The potential role of NK cell subpopulations
36. Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, in terleukin-18 (IL-18)
37. Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes
38. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor
39. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
40. Epitope focusing in the primary cytotoxic T cell response to Epstein-Bart virus and its relationship to T cell memory
41. Immediate early and early lyric cycle proteins are frequent targets of the Epstein Barr virus-induced cytotoxic T cell response
42. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV positive malignancies
43. Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during post-transplant lymphoproliferative disorder
44. Infusions of donor leukocytes to treat Epstein-Barr virus associated lymphoproliferative disorders after allogeneic bone marrow transplantation
45. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
46. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in aIlogeneic transplant recipients
47. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells
48. Functional analysis of the CD4+ T-cell response to Epstein Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLFI expression
49. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: A phase IB study
50. Human cytotoxic T cell responses against Epstein-Barr virus nuclear antigens demonstrated using recombinant vaccinia viruses
51. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccina: Implications for vaccine development